A Phase II Study of Adjuvant Cisplatin and Gemsitabine in patients with completely resected stage II-IIIA Non-Small Cell Lung Cancer
Not Applicable
- Conditions
- A Phase II Study of Adjuvant Cisplatin and Gemcitabine in patients with completely resected stage II-IIIA Non-Small Cell Lung Cancer
- Registration Number
- JPRN-UMIN000002855
- Lead Sponsor
- Toracic Medical Oncology of Toracic Center Cancer Instiute Hospital Japanese Foundation Cancer Reseach
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 55
Inclusion Criteria
Not provided
Exclusion Criteria
A recognized ILD or pulmonary fibrosis on X-rays.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1-year PFS
- Secondary Outcome Measures
Name Time Method toxicity complete rate of treatment